Professor Gau is currently Vice President of National Taiwan University (NTU) Hospital and Distinguished Professor of Psychiatry, Psychology, Epidemiology, Brain and Mind Sciences, Clinical Medicine, and Occupational Therapy at NTU, Taiwan. She got Ph.D. from Yale University in 2001. She was Director of Department of Psychiatry, NTU Hospital and College of Medicine (2009-2015), Director of Department of Medical Genetics (2015~2018) at NTUH, President of the Taiwanese Society of Child and Adolescent Psychiatry (2014-2018), Vice-President of International Association of Child and Adolescent Psychiatry, and Allied Professionals (IACAPAP, 2014-2018), and Secretary-General of IFPE (2012-2019). She has been the editor of several IACAPAP monographs since 2014. She is a fellow of INSAR, ACNP, and PRCP. Professor Gau’s main research interests include the psychiatric, genetic, and pharmacoepidemiology of attention-deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD). She has co-developed and prepared several Chinese versions of instruments for ADHD and ASD, conducted several studies on pharmacotherapy for ADHD, and been conducting follow-up, family, neuropsychological, neuroimaging, neurophysiological, microbiomes, metabolomics, and genetic studies on ADHD and ASD. Her collaborative research also covers animal (mice & flies) and cellular (iPSC) models. She has published more than 320 SCI/SSCI articles since 2001, of which she is the first author/corresponding author for more than 250 SCI/SSCI papers. She got Outstanding Research Award from the National Science Council (2012), National Taiwan University (2013), National Health Research Institute (2014), and NTUH (2016), Lifetime Academic Achievement Award from the Taiwanese Society of Psychiatry (2019), Physician Model Award from Taiwan Medical Association (Taiwan MA, 2020), Advancing Curiosity Award by Micron Foundation (2021), USA, 31st WANG MING-NING Award (2021), 30th Hsin-Lin award from Taipei Medical Association (Taipei MA) and Outstanding Research Award from the National Science and Technology Council (2023). Her ADHD consortium got NTUH Outstanding Research Award for contributing to medical research in 2019. She was awarded the Best Clinical Professor by the National Taiwan University College of Medicine Alumni Association in North America (2018), 2021 COVID-19 Prevention Human Right Service Award, 2022 COVID-19 Prevention Contribution Award from Taiwan MA, Special Contribution Award for COVID-19 Prevention from Taiwan MA, and National Innovation Award (2024). She received the 2020 IACAPAP Medal for her outstanding contribution to IACAPAP. Common Health Magazine elected her Doctor of the Year in 2022. She was ranked 2nd in Taiwan in Psychology and has also been recognized with Psychology Leader Award for 2023 by Research.com. She is the keynote/state-of-the-art/plenary speaker at over 20 international congresses. She and her team have presented their work in peer-reviewed Congress on over 860 occasions.
Clinical Trials：
1. Efficacy and safety of Concerta (Extended-Release Methylphenidate HCl) compared with Ritalin (Immediate-Release Methylphenidate HCL) in children with ADHD
2. Validation of the Chinese Version of the Conners’ Teacher Rating Scale Revised-Short Form and Conners’ Parent Rating Scale Revised-Short Form
3. Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride versus Placebo in Taiwanese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
4. Compliance Survey of ADHD Medication for Optimal Satisfaction
5. A 12-Month Prospective, Observational Study of Treatment Regimen and Quality of Life Associated with Attention Deficit Hyperactivity Disorder (ADHD)
6. Efficacy of atomoxetine in the neuropsychological tests among children with ADHD
7. Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years with Attention-Deficit/Hyperactivity Disorder Treated with Atomoxetine Hydrochloride
8. From immediate-release MPH to OROS MPH: The impact upon family of children and adolescents with ADHD
9. Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
10. An Open Study of Atomoxetine (LY139603) in Adult Subjects with Attention-deficit/Hyperactivity Disorder
11. Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
12. A Fixed Dose, Randomized, Double-blind, Placebo-Controlled Study of LY2216684 in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder
13. A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents with ADHD
14. An Extension Study to Evaluate the Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents with ADHD
15. A phase II tolerability and efficacy study of PDC-1421 treatment in adult patients with attention-deficit hyperactivity disorder (ADHD), part II